xalkori
pfizer europe ma eeig - crizotinib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
xalkori (▼) 200 mg/1 kapsula kapsula, tvrda
pfizer bh d.o.o. sarajevo - crizotinib - kapsula, tvrda - 200 mg/1 kapsula - 1 kapsula, tvrda sadrži: 200 mg krizotiniba
xalkori (▼) 250 mg/1 kapsula kapsula, tvrda
pfizer bh d.o.o. sarajevo - crizotinib - kapsula, tvrda - 250 mg/1 kapsula - 1 kapsula, tvrda sadrži: 250 mg krizotiniba
xalkori 200mg kapsula, tvrda
"evropa lek pharma" doo podgorica - krizotinib - kapsula, tvrda - 200mg
xalkori 250mg kapsula, tvrda
"evropa lek pharma" doo podgorica - krizotinib - kapsula, tvrda - 250mg